Celularity Inc. announced that Adrian Kilcoyne, M.D., M.P.H., M.B.A., has been appointed Executive Vice President, Chief Medical Officer (CMO) and Head of Global Affairs, Patient Safety and Patient Affairs, effective today. Dr. Kilcoyne brings over 15 years of clinical experience to Celularity, having previously served in R&D, medical affairs, and commercialization roles, primarily focused on oncology. He has a track record of advancing early-stage clinical programs through commercialization and will provide senior leadership to advance Celularity's clinical pipeline toward U.S. Food and Drug Administration (FDA) approval.

Most recently, Dr. Kilcoyne served as the Chief Medical Officer of Humanigen, where he was responsible for building its oncology and immunology portfolio focused on the cytokine pathway, CAR-T therapy related toxicity, and antibody drug conjugates (ADCs) in solid tumors. Before that, he served as an integral member of the executive team at AstraZeneca as the Vice President of Global Oncology Evidence Generation and External Alliances. During his time at AstraZeneca, he was responsible for the creation, development, and delivery of the fully integrated Global Evidence strategy.

Dr. Kilcoyne holds an M.D. from Trinity College in Dublin, an M.P.H. from the University of London, and an M.B.A. from Warwick Business School. Along with multiple publications in peer review journals, he co-authored the Oxford Specialist Handbook of Pharmaceutical Medicine.